Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Celyad Oncology SA (CYAD)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.9250+0.0250 (+1.32%)
At close: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close1.9000
Open1.9000
Bid1.7200 x 1000
Ask2.2400 x 1000
Day's Range1.7900 - 1.9250
52 Week Range1.5100 - 5.4100
Volume85
Avg. Volume5,440
Market Cap43.493M
Beta (5Y Monthly)1.19
PE Ratio (TTM)N/A
EPS (TTM)-1.5070
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.62
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CYAD

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Celyad Oncology SA
    Daily – Vickers Top Buyers & Sellers for 03/21/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    3 months agoArgus Research
View more
  • GlobeNewswire

    Celyad Oncology Announces Leadership Updates

    MONT-SAINT-GUIBERT, Belgium, June 24, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Board of Directors has named Hilde Windels as Chairwoman of the Board of Directors, effective immediately. Ms. Windels has been a member of the Board of Directors since May 2018. Ms. Windels serves on mul

  • Business Wire

    Celyad: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

    MONT-SAINT-GUIBERT, Belgium, May 31, 2022--Regulatory news: Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the "Company"), a clinical-stage biotechnology company focused on the discovery and the development of Chimeric Antigen Receptor T cell (CAR T) therapies for cancer, announced that 350 registered shares benefit from a double voting right as of May 25, 2022. As a result, the Company’s total number of voting rights is now 24,962,331.

  • GlobeNewswire

    Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

    MONT-SAINT-GUIBERT, Belgium, May 31, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and the development of Chimeric Antigen Receptor T cell (CAR T) therapies for cancer, announced that 350 registered shares benefit from a double voting right as of May 25, 2022. As a result, the Company’s total number of voting rights is now 24,962,331. This information is published in accordance with Article 1

Advertisement
Advertisement